DENTLUXUE Holdings
01Home 02The Group 03Leadership 04Acquisition Strategy 05Our Thesis 06Careers 07Contact

This site is presented as a single continuous document because JavaScript is unavailable.

Building the new era of superior dental care.

DentLuxue Holdings acquires premium independent dental practices and groups across the United Kingdom and integrates them, with rigour, into a single clinical and operational platform — backed by disciplined capital and genuinely transformative technology.

0.00bn

UK high-street dentistry, 2023/24

£12.16bn, up 9.2% year on year. LaingBuisson, Dentistry UK, 7th ed., Sept 2025.

0%

Of that market is private-pay

£8.4bn private against £3.78bn NHS; private-pay grew £965m in the year.

0%

Of UK adults saw an NHS dentist

18.8m adults in the 24 months to 31 March 2026. NHSBSA, published 27 Aug 2026.

00%

Corporate share of dental transactions

7% of 2025 completions; c.20% of the 2026 live pipeline. Christie & Co, Jan 2026.

The Operating Model

One group, built around the practice.

Two disciplines, and only two: acquisition and integration. We acquire premium independent practices and groups, and integrate them into one clinical and operational platform — each practice keeping the identity its principal built, everything behind it consolidated.

Acquisition — what we buy

Premium independent practices

Established clinical reputations, loyal private patient bases, principals with no obvious successor.

Established small groups

Two to ten sites with proven management and consistent standards, constrained by capital.

DentLuxue Holdings

The Platform

Integration — what we bring

Capital & corporate discipline

Underwriting, financing, governance and reporting held to institutional standard from the first acquisition.

Clinical & digital architecture

Shared clinical governance, digital workflow, diagnostics and data — deployed as infrastructure, not as a bolt-on.

The output

A unified network delivering clinical excellence at scale

The Market

A £12 billion market, and a supply side that has not caught up.

Demand has moved decisively private. Ownership has not consolidated with it. That gap is the opportunity, and it is measurable.

The full thesis
Private-pay dentistry£8.40bn

69% of the UK high-street market, and growing — up £965m on the prior year.

NHS dentistry£3.78bn

31% of the market. Access constrained: 40% of adults seen in 24 months.


Corporate share of completions, 20257%
Corporate share of 2026 live pipelinec.20%

Corporate appetite is returning to a market it stepped back from. The window in which vendors can still choose their acquirer is finite.

Sources: LaingBuisson, Dentistry UK Market Report, 7th edition, 18 September 2025 (FY2023/24 data); Christie & Co, Business Outlook 2026 — Dental, 15 January 2026; NHS Business Services Authority, NHS Dental Statistics for England 2025/26, 27 August 2026.

Who We Serve

Three constituencies. One structure.

Acquisition and integration are the two disciplines; these are the three parties to them, and what each one gets from the way the Group is built.

01

Practice principals

A considered exit with genuine continuity for your team and your patients — structured around what you actually want from the transition, not around a template.

How we acquire
02

Clinical partners

Participation in the group itself rather than in a single site — the value you help create across the whole platform, not only within your four walls.

Join us
03

Institutional counterparties

Lenders, advisers and intermediaries dealing with a board that has closed this transaction type before, and governance built to institutional standard from day one.

Meet the board

Board, Executive & Non-Executive

A cadre of operators, not a list of advisers.

Between them: leadership of Portman Dental Care, myDentist and IDH, Dentex and Together Dental, alongside Wolters Kluwer, RWS Holdings, UBS, HSBC, Citigroup and IBM.

Founders & Board

Four Principals
WQWaheed Qaiser

Co-Founder & Chairman

Waheed Qaiser

Three decades as Chairman, Chief Executive and Managing Director across the world’s principal financial centres; investment banking, M&A, asset and wealth management.

ABAndrew Brode

Co-Founder & Vice Chairman

Andrew Brode

Chartered accountant; former Chief Executive of Wolters Kluwer (UK) PLC. Acquired and scaled RWS Holdings PLC, Learning Technologies Group plc and GRC Group International PLC.

JPJoel Pall

Founding Principal

Joel Pall

Founder of DentLuxue. Identified UK private dentistry as a market ripe for consolidation, professionalisation and a genuinely differentiated service model.

MSManvedeep Singh

Co-Founder & Head of M&A

Manvedeep Singh

British entrepreneur, adviser and professional across healthcare, technology and finance; interests spanning care villages, residential care, home care, cybersecurity and artificial intelligence.

Executive Team

Five Officers
ASAndy Sloan

Chief Executive Officer

Andy Sloan

Statutory board director of Portman Dental Care through its most active acquisition phase; board signatory on more than 120 practice acquisitions. Latterly Managing Director, Dental EMEA at Agilio Software.

LTSheikh Lutfi Talib

Chief Financial Officer

Sheikh Lutfi Talib

Partner of Maxim Corporate Finance LLP; 35 years across audit, corporate finance and tax. FCCA, CPA (Australia), MCIS; co-founder of Chancery Capital Markets plc.

SWSteve Williams

Chief Operating Officer

Steve Williams

GDC-registered dentist; over ten years at board level as Clinical Director at myDentist and Chief Operating Officer at Together Dental. Oversight of more than 350 completed acquisitions.

JBDr Jason Bedford

Chief Clinical Officer

Dr Jason Bedford

GDC Specialist Register in Endodontics since 2000. Executive experience across the IDH Group, Dental Directory and Dentex; co-founder of Today’s Dental and founder of D2D Endo.

Chief Legal Officer

To be confirmed

Appointment in progress. This entry is updated when the appointment is executed and, where required, filed at Companies House.

Non-Executive Team

Three Directors
LWLindsey Walker

Non-Executive Director

Lindsey Walker

Former Chief Operating Officer of IDH Ltd, parent of myDentist, accountable for £300m+ of NHS contract value to 5 million patients; grew the estate from 60 to over 600 clinics.

JLJonathan Loretto

Non-Executive Director

Jonathan Loretto

Global commercial and technology leader. Chief Growth Officer at GFT; previously global security lead at HSBC Digital and accountable Partner at IBM for the European Blockchain Delivery Centres.

Non-Executive Director

To be confirmed

Appointment in progress. This entry is updated when the appointment is executed and, where required, filed at Companies House.

Full biographies

Do you own a practice you have spent a career building?

A confidential first conversation, under NDA, with no obligation on either side.

Start a conversation

The Group

A disciplined platform for a fragmented market.

DentLuxue Holdings Limited is a private investment group established to capitalise upon a structural inflection point in the United Kingdom’s private dental sector, uniting internationally experienced professionals across healthcare, mergers and acquisitions, technology, institutional capital markets and professional services.

Mandate

What we do.

The Platform One clinical and operational architecture, applied to every practice in the Group.

Our mandate is threefold: to acquire premium independent dental practices; to integrate them, with rigour, into a unified clinical and operational platform; and to deploy technology that is genuinely transformative rather than cosmetic — the operating architecture upon which category leadership is built and sustained.

The opportunity rests on durable structural forces. Sustained NHS constraint has catalysed a lasting shift toward private care while rising patient expectations broaden the market, with particular momentum in higher-margin specialities. Against that demand, the supply side remains conspicuously fragmented: independent operators face regulatory burden, staffing constraint and the capital cost of modernisation, and comparatively few can fund all three at once.

Through horizontal and vertical integration we intend to deploy digital platforms, robotics and applied artificial intelligence to drive measurable improvement in clinical outcomes, operational efficiency and patient experience — clinical excellence delivered in environments of understated luxury.

Principles

What we hold to.

I

Clinical primacy

Every acquisition is judged first on the quality of care it delivers. A practice that fails on clinical grounds is not rescued by its arithmetic.

II

Identity preserved

Each practice keeps the clinical identity its principal built. What consolidates is the infrastructure behind it, not the name above the door.

III

Operational discipline

Value is created by hands-on stewardship after completion, not by the announcement of a transaction.

IV

Ownership, not custody

The Group is assembled to be held and compounded, not dressed for a rapid onward sale.

Governance

Committees and charters.

Institutional discipline by design. Each committee operates to a defined mandate as the Group’s governance matures alongside its estate.

Executive Committee
Day-to-day management and strategic direction of the Group.
Investment Committee
Underwrites all material acquisitions against defined criteria, and owns post-acquisition monitoring against the case on which each was approved.
Clinical Governance Committee
Sets and safeguards clinical standards, quality and patient safety across every practice in the Group. Chaired by the Chief Clinical Officer.
Audit & Risk Committee
Financial integrity, internal control, and the Group’s relationship with its external auditors.
Nomination & Remuneration Committee
Succession, board composition, and the alignment of remuneration with long-term value creation.
Conflicts & Compliance
Maintains the conflicts register and oversees compliance with the regulatory perimeter within which the Group operates.

The Group is at an early stage. Committee mandates are established in principle; formal charters are adopted, and memberships appointed, as the corresponding activity commences.

Leadership

Leadership you can trust.

The Board and executive team assembled for DentLuxue draws on the leadership of Portman Dental Care, myDentist, IDH, Dentex and Together Dental, and on capital markets experience at UBS, HSBC and Citigroup. Two appointments remain open and are identified as such.

Founders & Board

Co-Founders and Principals
WQWaheed Qaiser

Co-Founder & Chairman

Waheed Qaiser

A senior financial services executive — having served as Chairman, Chief Executive and Managing Director — with over three decades of achievement across the world’s principal global financial centres. His expertise spans investment banking, mergers and acquisitions, asset and wealth management, and corporate finance.

Qaiser played a pioneering role in the establishment and promotion of Islamic banking in Europe, commencing in 1998 as Lead Founder of the first Islamic bank in the United Kingdom. He has led management teams at QCC, Chapterhouse, Pairstech, IBB, IIBU, UBS, HSBC and Citigroup.

A founding member of the Bank of England Working Party on Islamic Mortgages, he was instrumental in securing an amendment to the British stamp duty regime abolishing the double imposition on Islamic mortgage structures. He further served as a Founding Member of the UK Technical Group at the Securities Investment Institute, contributing to the development of the Islamic Finance Qualification in corporate finance. He co-authored a definitive text on Islamic retail banking and finance published by Euromoney, London.

Investment BankingM&ACapital MarketsGovernance
ABAndrew Brode

Co-Founder & Vice Chairman

Andrew Brode

An accomplished entrepreneur and investor. He qualified as a Chartered Accountant and began his career with Arthur Andersen and Rothschilds, before moving into business publishing as Managing Director of Croner Publications, which he built up and sold to Wolters Kluwer. He later became Chief Executive of Wolters Kluwer (UK) PLC, expanding the business to UK sales of £80 million.

He went on to acquire and scale several market-leading businesses including Eclipse Publications, RWS Holdings PLC, Learning Technologies Group plc and GRC Group International PLC, and has held senior roles with Axco Insurance Information Services and Electric Word plc — driving growth and successful exits across multiple industries.

Buy-and-BuildPublic MarketsExitsChartered Accountant
JPJoel Pall

Founding Principal

Joel Pall

Jóel Páll Viðarsson, known professionally as Joel Pall, began his career in the most unpretentious of circumstances — a formative grounding that instilled a deep appreciation for operational discipline, service excellence and the value of purposeful endeavour. Through a succession of increasingly senior responsibilities he became a steward of purposeful growth, driven by an enduring commitment to converting opportunity into lasting value.

With broad experience across diverse industries and international markets, Pall elected to direct his expertise toward the United Kingdom and, specifically, toward private dentistry — a market he identified as ripe for consolidation, professionalisation and the application of a genuinely differentiated service model.

His vision is unambiguous: to establish a dental brand capable of delivering a standard of clinical and hospitality experience that transcends contractual obligation. To realise it, he founded DentLuxue, with the stated aim of transforming a fragmented and underserved market into a single thriving enterprise built on clinical excellence, partnership and long-term value creation.

FounderStrategyInternational
MSManvedeep Singh

Co-Founder & Head of Mergers and Acquisitions

Manvedeep Singh

Manvedeep Singh, known professionally as Manav, is a British entrepreneur, adviser and professional whose experience extends across healthcare, technology, finance and adjacent sectors. Endowed with global interests and a keen strategic mind, he combines foresight with measured and decisive execution.

Singh’s present interests encompass care villages, residential care homes, home care services, e-commerce ventures, cybersecurity, professional service firms and artificial intelligence businesses, among other endeavours. He brings to each engagement a rigorous approach to capital deployment, operational oversight and value creation, and serves as Founder, Adviser and Non-Executive Director to various enterprises.

OriginationDeal StructuringHealthcareTechnology

Executive Team

Officers of the Group
ASAndy Sloan

Chief Executive Officer

Andy Sloan

One of UK dentistry’s most experienced acquisition and growth leaders, with more than fifteen years at the centre of the sector’s consolidation. His career spans hospitality, banking and accountancy before dentistry — a grounding that shaped a commercial philosophy built on service excellence, financial discipline and operational rigour.

Sloan served as a statutory board director of Portman Dental Care through the most active phase of its acquisition-led growth, sitting as board signatory on more than 120 practice acquisitions and personally leading between thirty and forty transactions end to end — from origination and negotiation through due diligence, completion and integration. His sector experience further includes senior leadership roles at Henry Schein and DBG, and most recently Managing Director, Dental EMEA at Agilio Software, whose platforms serve more than 5,000 practices and nineteen of the twenty largest dental groups in the United Kingdom.

Beyond his executive career he is Executive Editor of Dentist Times, chairs the dental stream of the UK Healthcare Summit and the Dentist Times Owners Club programme, and is the author of The Accidental Dental Strategist, publishing in 2027. As Chief Executive of DentLuxue he leads on the principle that the best dental acquisitions are partnerships, not purchases.

120+ AcquisitionsIntegrationSector Networks
LTSheikh Lutfi Talib

Chief Financial Officer

Sheikh Lutfi Talib

A partner of Maxim Corporate Finance LLP and a financial services entrepreneur with a career spanning 35 years. He began in accounting at Ernst & Whinney (now Ernst & Young) before specialising in financial services across successive UK appointments, providing business consultancy to investment houses and property companies and formulating pension scheme and corporate structures for overseas companies.

In 2001 he joined Shaw Walker as Audit Partner, and from 2004 established Ashfields — subsequently rebranded McMillan Woods — focusing on business consultancy, corporate finance, audit, tax and accounts. He is co-founder of Montagu Financial Services (2005), Maxim Corporate Finance LLP (2007), Chancery Capital Markets plc (2008) and PP Investco Limited (2009).

He holds an MBA from Middlesex University and a degree in International Business and Management of Companies from Pace University. He is a Fellow of the Association of Chartered Certified Accountants, a Certified Public Accountant in Australia, a Member of the Institute of Singapore Chartered Accountants, a Member of the Chartered Institute for Securities and Investment, a Member of the Chartered Institute of Management, and a Fellow of the Royal Society of Arts.

Corporate FinanceAuditFCCAStructuring
SWSteve Williams

Chief Operating Officer

Steve Williams

Stephen Williams, known professionally as Steve, is an experienced dental leader with more than three decades of clinical, operational and private equity expertise. A qualified dentist with active GDC registration, he has led large multisite organisations, driven significant commercial growth and built high-performing teams across the United Kingdom’s dental sector.

He is one of few dentists in the UK to have held board positions in private equity backed dental corporates in both a clinical and an operational role. Serving for over ten years at board level — as Clinical Director at myDentist and Chief Operating Officer at Together Dental — his tenure included major improvements in governance, regulatory compliance and clinician retention, driving organic growth, leading successful integrations and building external reputation. He has had oversight of over 350 completed acquisitions and is an established consultant advising investors on operational and clinical due diligence in the dental sector.

GDC Registered350+ AcquisitionsMultisite OperationsClinical DD
JBDr Jason Bedford

Chief Clinical Officer

Dr Jason Bedford

An experienced dental clinician, entrepreneur and executive leader with more than 30 years’ experience across clinical practice, dental business, education and the wider UK dental sector. He qualified from the University of Manchester in 1992 and, following five years in general dental practice and a further three years of postgraduate training, was admitted to the General Dental Council Specialist Register in Endodontics in 2000.

His executive and commercial experience spans the IDH Group, Dental Directory and Dentex, and he was a co-founder of Today’s Dental. In 2006 he founded D2D Endo, an online endodontic education and supply business which became a market leader in its sector, serving dental professionals in 44 countries and training more than 8,000 dentists; it was acquired by Sendoline AB in 2011.

As Chief Clinical Officer he is responsible for ensuring clinical excellence and patient care remain central to the Group’s strategy as it grows: building high-performing clinical teams, supporting clinicians and practice owners, developing scalable clinical systems, and creating an environment in which practices can grow without losing the individual culture, professional standards and patient relationships that made them successful.

Specialist — EndodonticsClinical GovernanceDental Education

Chief Legal Officer

To be confirmed

The Chief Legal Officer appointment is in progress. This entry will be completed when the appointment is executed and, where required, filed at Companies House.

Non-Executive Team

Independent Oversight
LWLindsey Walker

Non-Executive Director

Lindsey Walker

A C-suite director experienced in both private and public sectors, with a background comprising national retail roles, director positions within children’s services providers, NHS-affiliated primary care, and various transformational roles.

As Chief Operating Officer of IDH Ltd, the parent company of myDentist, she was accountable for the delivery of £300m+ of NHS contract value nationally to 5 million patients, together with the operation and integration of all practices, increasing the estate from 60 to over 600 clinics. She also established a complete operations team to facilitate this, providing a blueprint across the industry.

As Non-Executive Director of DentLuxue she provides independent oversight, strategic counsel and rigorous challenge across the business, assisting in the development of an acquisition-led growth model.

Scale Operations60 → 600 ClinicsNHS ContractingIntegration
JLJonathan Loretto

Non-Executive Director

Jonathan Loretto

A global commercial and technology leader with experience advising firms across Europe, North America and Asia Pacific through their transformation from traditional enterprises to innovative and agile businesses. He is an advisor to several charitable boards on technology utilisation, business operations and market engagement.

As Chief Growth Officer at GFT he managed the end-to-end restructure of the business from sales through to the professional services unit, resulting in a doubling of revenue and tripling of profits over two years. Prior to GFT he led security globally at HSBC Digital, creating a foundational security architecture and flexible modular authentication platform that reduced operational complexity across 38 markets. At IBM he was the accountable Partner for the redevelopment of the European Blockchain Delivery Centres, enabling the construction of large consortia including WeTrade, TradeLens, LedgerConnect and Vinturas, delivering £100m in ARR, and led the global recovery of Maersk’s IT systems in eight weeks following the NotPetya attack.

He holds an MSc in Information Systems and Management and is a former lecturer at Warwick Business School.

Technology StrategyCyber SecurityTransformation

Non-Executive Director

To be confirmed

The third Non-Executive appointment is in progress. This entry will be completed when the appointment is executed and, where required, filed at Companies House.

Statutory directorships and persons with significant control are a matter of public record at Companies House under registration number 17448083; the register, not this page, is determinative of who holds office at any given time.

Acquisition Strategy

We work with a small number of principals each year.

At a pace that respects the business being sold and the people inside it. Behind that pace sits a single governed plan — what the platform must be capable of, how a practice is found, underwritten, financed and integrated, and how the risk in each of those is held. Every process begins with a confidential conversation and a mutual non-disclosure agreement, and proceeds only if both sides want it to.

The Strategy

One plan, governing every acquisition.

The Acquisition Strategy is the Group’s integrated plan for building the platform. It sets the capability the platform must hold before it takes on the next practice, the approach by which practices are acquired, the commercial basis on which they are bought, the clinical and technical architecture they are brought onto, the support the centre owes them afterwards, and the risks attaching to each. It is the document the Investment Committee approves against, and the document it monitors against once a practice is inside the Group.

Capability needs
What the platform must be able to do before it acquires again: clinical governance that holds, compliance that survives inspection, finance and reporting that close on time, digital workflow that a new site can be moved onto, and the people to run all four. Capability is built ahead of volume, never behind it. A practice is not acquired into a platform that cannot yet carry it.Precondition
Acquisition approach
Direct relationships with principals, supported by intermediary coverage, rather than auction participation. Every opportunity is assessed against the same five dimensions and underwritten to a written case before any offer is made. A small number of transactions each year, each of which the Group can integrate properly.How we buy
Business approach
Consideration structured to the vendor’s objectives and the profile of the business rather than to a template; financing arranged transaction by transaction; equity participation in the Group available to principals and clinicians who want a stake in what the whole platform builds. No personal guarantees are given by any founder to lenders.Commercial basis
Technical strategy
Clinical workflow, diagnostics and data deployed as the architecture a practice runs on, not as a bolt-on after completion. Technological differentiation is treated as a source of clinical outcome and operating margin, and is underwritten as such: every system carries an expected effect on capacity, conversion or cost, and is measured against it.Differentiation
Support strategy
What the centre owes a practice once it is inside: compliance and clinical governance, procurement, recruitment, marketing, finance and reporting. The test is simple and is applied at every review — the practice must be demonstrably better supported than it was on the day before completion.Obligation
Risk management
Each risk carries a named owner and a monitored position: regulatory exposure, clinician retention, integration load, financing and the competitive market for the same assets. The register is reviewed by the Board, and a risk that cannot be owned is a reason not to transact.Governance

Lifecycle

Phases, and the work each one carries.

Each phase is defined by its work effort and closed by a single event. Nothing advances because time has passed; it advances because the event has occurred.

I

Origination

Market mapping, direct relationships with principals, intermediary coverage.

Closes on: a signed NDA and a business worth underwriting.

II

Underwriting

Clinical, financial, regulatory and people assessment against the five dimensions; the written case put to the Investment Committee.

Closes on: an approved indicative offer.

III

Execution

Diligence, structure, financing and documentation, run by professional advisers to a defined timetable.

Closes on: completion.

IV

Integration

Governance, clinical standards, systems and reporting brought onto the platform, led by people who have done it before.

Closes on: the practice reporting on Group systems against the case on which it was approved.

V

Optimisation

Capacity, clinical mix, digital workflow and diagnostics worked through to the case, then beyond it.

Closes on: performance ahead of the underwritten case — and capability released for the next acquisition.

The phases are sequential in respect of any one practice and concurrent across the portfolio: a practice in optimisation funds the capability that underwrites the next origination. That relationship, rather than a calendar, is what governs the rate at which the Group acquires.

Why Now

Four shifts, converging.

Succession without successors
A generation of independent principals is approaching retirement. Practice values have outpaced what an individual associate can fund alone, so the internal succession that once absorbed these businesses no longer clears.Structural
Demand has moved private
Private-pay dentistry is now 69% of the UK high-street market at £8.4bn, and grew £965m in a single year. NHS access remains constrained: 40% of adults were seen in the 24 months to 31 March 2026.Measured
The corporate window is reopening
Corporate buyers accounted for only 7% of completed dental transactions in 2025, but around 20% of the 2026 live pipeline. Vendors who transact now still choose their acquirer; in a hotter market they are chosen.Timing
A widening capability gap
The distance between practices that have invested in modern clinical and digital systems and those that have not is widening every year, and the cost of closing it alone is now beyond most single-site operators.Operational

Sources: LaingBuisson, Dentistry UK Market Report, 7th ed., 18 September 2025; Christie & Co, Business Outlook 2026 — Dental, 15 January 2026; NHSBSA, NHS Dental Statistics for England 2025/26, 27 August 2026.

Where We Invest

Three categories, each assessed on its own terms.

01

Premium single sites

Individual practices with an established premium reputation, a strong private-patient base and a principal who wants the business to continue rather than be absorbed.

02

Established groups

Multi-site groups with proven management, consistent standards and further room to scale — where the constraint is capital and infrastructure rather than capability.

03

Defined upside

Well-run practices with quantifiable headroom — capacity, specialism or private conversion — where the plan to realise it can be written down before completion, not after.

Underwriting

Five dimensions. Every time.

No opportunity reaches the Investment Committee without a view on all five. A practice that is strong on four and weak on one is a conversation, not an offer.

Clinical mix
The balance, quality and durability of treatments provided, and their exposure to policy.
Facilities & technology
The standard of surgeries, equipment, premises and the systems the practice actually runs on.
Regulatory standing
CQC and GDC position, clinical records, indemnity, and the integrity of the compliance history.
People
The strength and stability of the clinical and support team, and the retention risk on completion.
Quality of earnings
The durability of underlying EBITDA, its dependence on the principal, and what survives their departure.

Value Creation

Where the return is actually made.

Four levers, in sequence. The first is arithmetic; the last three are work. Illustrative and indexed — not a forecast of any specific transaction.

100Entry EBITDA at acquisition
+18Operating leverage & procurement
+14Clinical mix & capacity utilisation
+11Digital workflow & diagnostics
143Platform EBITDA, pre multiple

Indexed illustration of the levers the Group intends to apply, shown at 100 = entry EBITDA. It is a description of method, not a projection, and carries no representation as to outcome. Multiple arbitrage between single-asset and platform valuations is deliberately excluded: it is a consequence of scale, not a lever management controls.

Process

From first conversation to completion.

Five stages. You can stop at any of them, and a number of conversations properly end at stage two — which is the point of running it this way.

01

Introduction, under NDA

A confidential conversation to understand the practice and, more importantly, what you want the transition to achieve. Nothing is shared beyond the immediate team.

02

Information exchange

We set out how DentLuxue works and what ownership within the Group means in practice. You share the operating and financial picture necessary to form a view.

03

Indicative offer

A written, non-binding indication setting out proposed structure and terms. Consideration is structured to the vendor’s objectives and the profile of the business; we do not publish a single template.

04

Due diligence

Legal, financial, clinical and regulatory diligence run by professional advisers to a defined timetable, structured to disturb the practice and its team as little as possible.

05

Completion & integration

Terms finalised, transaction completed, and integration led by people who have done it before — on a timeline agreed with you rather than imposed on you.

Considering a sale, now or within three years?

The earlier the conversation, the more of it you control.

Speak to us in confidence

Our Thesis

Why this market, why this structure, and what could go wrong.

This page sets out the Group’s reasoning and the principal risks to it. It is provided for general information about DentLuxue and its strategy. It is not an offer, an invitation, or an inducement to engage in investment activity of any kind.

The Opportunity

Fragmentation is not a slogan here. It is the arithmetic.

The UK high-street dental market was worth £12.16bn in 2023/24 and grew 9.2% year on year. Independent ownership still dominates it. Corporate buyers took only 7% of completions in 2025.

Three forces converge on UK dentistry at once. A generation of independent principals is approaching retirement with no obvious successor and valuations beyond associate reach. Sustained NHS access pressure continues to push steady demand toward private and mixed-economy care. And a widening gap has opened between practices that have invested in modern clinical and digital systems and those that have not.

Disciplined capital, deployed properly, sits at the intersection of all three. The scarce commodity is not money — it is an acquirer that a retiring principal is willing to hand a career to, with the operating capability to make the second five years better than the first.

Approach

How we intend to create value.

01

Disciplined underwriting

Every acquisition assessed on clinical quality and operational fundamentals against a written case, not on growth for its own sake. Practices are monitored after completion against the case on which they were approved.

02

Hands-on integration

Led by people who have completed it before, at scale, in this sector — over 350 acquisitions of oversight between the Chief Operating Officer and Chief Executive alone.

03

Technology as infrastructure

Early, real investment in the systems each practice runs on: clinical workflow, diagnostics, data. Deployed as infrastructure from the outset, not bolted on once the deal has closed.

Risk

Stated plainly, because they are real.

A thesis that lists no risks is marketing. These are the five that matter, and the Group’s view of each.

Execution — the principal risk
DentLuxue was incorporated on 9 September 2026 and has completed no acquisitions. The thesis is unproven until the first practices are acquired and integrated, and a board’s prior record is not the Group’s record.High
Competition & regulatory review of private pricing
On 2 April 2026 the Competition and Markets Authority opened a review of the private dentistry market, examining access, consumer choice, pricing, business conduct, redress and regulation. Any consolidator whose case rests on premium private pricing must assume that pricing, transparency and complaint handling will be scrutinised, and build to that standard now rather than later.Material
NHS contract reform
Reform and the political focus on access could reshape the economics of NHS-facing practices at short notice, in either direction. Mixed practices are underwritten on their private economics, with NHS income treated as an option rather than a foundation.Material
Well-capitalised competition
Experienced consolidators — among them myDentist, backed by Bridgepoint, and PortmanDentex — compete for the same assets with established origination and, in several cases, longer balance sheets. Corporate share of the pipeline is rising, which raises entry prices as well as opportunity.Ongoing
Two simultaneous integrations
Consolidating independent practices is operationally demanding by itself. Layering meaningful technology deployment on top adds a second, genuine execution challenge, and the two compete for the same management attention in the same window.Ongoing

Sources: Competition and Markets Authority market review of private dentistry, announced 2 April 2026; LaingBuisson, Dentistry UK Market Report, 7th ed., September 2025; Christie & Co, Business Outlook 2026, January 2026. Named competitors are identified for context only.

Questions about the Group or its strategy?

We are content to discuss the thesis and the team with serious counterparties.

Make an enquiry

Important. Nothing on this page or elsewhere on this website constitutes an offer or invitation to subscribe for or purchase any security, nor a financial promotion within the meaning of section 21 of the Financial Services and Markets Act 2000, nor any inducement to engage in investment activity. No securities of DentLuxue Holdings Limited are being offered by means of this website. Any such offer, if made, would be made only to eligible persons, by means of formal documentation, and in accordance with applicable law. Certain statements on this website are forward-looking and reflect present intention only; actual results may differ materially and no reliance should be placed upon them.

Careers

Build it, rather than inherit it.

DentLuxue is early. That is the offer and the risk in a single sentence: the people who join now shape what this becomes. We are interested in people who care about dentistry, about doing acquisitions properly, and about building something that outlasts its founders.

Disciplines

Where we are building teams.

Clinical leadership
Setting and safeguarding the standard every acquired practice operates to, and supporting the clinicians who deliver it.
Operations & integration
Taking a newly acquired practice from completion to a smoothly running part of the Group, without breaking what made it worth buying.
Corporate, finance & legal
Sourcing, structuring and closing acquisitions, and running the holding company to institutional standard.
Technology & data
Building and integrating the clinical and operational platforms every practice in the Group will run on.

Submit your candidacy.

We are not running fixed vacancies yet. Please send a short note on why disciplined dental consolidation interests you, and we will ask for a CV if there is a conversation to be had. Brevity is a signal.

Get in touch

Contact

Start a conversation.

Practice principals, clinical partners, advisers and intermediaries. Enquiries are handled by the executive team directly and treated as confidential from the first message.

Correspondence

Write directly to the desk that handles the matter. Every enquiry is treated as confidential from the first message, and an NDA is offered before any information is exchanged.

Payment security. DentLuxue Holdings Limited will never notify a change of bank details by email. Any communication purporting to do so should be verified by telephone, against a number obtained independently, before any payment is made.

Registered office

  • Registered name

    DentLuxue Holdings Limited

  • Registered in

    England and Wales · Company number 17448083

  • Registered office

    42–44 Bishopsgate
    London EC2N 4AH
    United Kingdom

Legal

Privacy Policy

Legal

Terms of Use

Legal

Cookie Policy